Vanguard Group Inc. Decreases Stock Position in Teladoc Health, Inc. $TDOC

Vanguard Group Inc. cut its stake in Teladoc Health, Inc. (NYSE:TDOC) by 1.9% in the fourth quarter, HoldingsChannel reports. The firm owned 21,483,707 shares of the health services provider’s stock after selling 427,243 shares during the quarter. Vanguard Group Inc. owned approximately 0.12% of Teladoc Health worth $150,386,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc boosted its holdings in Teladoc Health by 412.1% in the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 3,210 shares during the period. Aster Capital Management DIFC Ltd boosted its holdings in Teladoc Health by 101.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after purchasing an additional 2,425 shares during the period. Bayforest Capital Ltd acquired a new position in shares of Teladoc Health during the third quarter worth $58,000. KBC Group NV grew its stake in shares of Teladoc Health by 88.3% during the fourth quarter. KBC Group NV now owns 9,632 shares of the health services provider’s stock worth $67,000 after purchasing an additional 4,516 shares in the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in shares of Teladoc Health during the third quarter worth $75,000. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TDOC. Wells Fargo & Company lowered their target price on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, February 26th. Barclays lowered their target price on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, March 26th. Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Thursday, February 26th. JPMorgan Chase & Co. decreased their price objective on shares of Teladoc Health from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, March 13th. Finally, TD Cowen decreased their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $7.53.

Insider Transactions at Teladoc Health

In related news, CEO Charles Divita III sold 27,731 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the transaction, the chief executive officer directly owned 364,784 shares of the company’s stock, valued at $2,002,664.16. This represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.70% of the stock is owned by corporate insiders.

Teladoc Health Price Performance

Shares of NYSE:TDOC opened at $6.93 on Tuesday. The company has a 50-day simple moving average of $5.61 and a 200-day simple moving average of $6.37. Teladoc Health, Inc. has a one year low of $4.40 and a one year high of $9.77. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -7.14 and a beta of 2.08.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The firm had revenue of $613.85 million for the quarter, compared to analysts’ expectations of $611.04 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The company’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, analysts predict that Teladoc Health, Inc. will post -0.92 EPS for the current year.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.